| ANALYTICAL REPORT |
|
| Year : 2012 | Volume
: 8
| Issue : 2 | Page : 303-305 |
|
|
Severe perirenal hematoma in a patient with a single kidney treated with sunitinib for metastatic pancreatic neuroendocrine tumor
Jon Zugazagoitia1, Javier Sastre2, Jerónimo Barrera1, Beatriz García1, Eduardo Díaz-Rubio1
1 Department of Medical Oncology, Hospital Clinico San Carlos, Centeraffíliated to the Red Temática de Investigación Cooperativa (RD06/0020/0021). Instituto Carlos III, Spanish Ministry of Science and Innovation, Madrid, Spain
2 Department of Radiology, Hospital Clinico San Carlos, Centeraffíliated to the Red Temática de Investigación Cooperativa (RD06/0020/0021). Instituto Carlos III, Spanish Ministry of Science and Innovation, Madrid, Spain
Correspondence Address:
Jon Zugazagoitia
Department of Medical Oncology, Hospital Clínico San Carlos, Profesor Martín Lagos, s/n 28040 - Madrid
Spain
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.98997
|
|
|
A better understanding of the angiogenic process has markedly expanded the use of antiangiogenic therapy in many solid tumors. It is known that there is a close relationship between cancer disease, vascular homeostasis, angiogenesis and coagulation cascade. In this setting, antiangiogenic therapy could interfere and potentially increase the risk of bleeding or thromboembolic events. Sunitinib is an orally available smallmolecule multikinase inhibitor recently approved for the treatment of unresectable or metastatic, well-differenciated pancreatic neuroendocrine tumors with disease progression in adults. Here we present the first case of a severe perirenal hematoma in a patient treated with sunitinib for metastatic pancreatic neuroendocrine tumor. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
